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Abstract 
Casein kinase II is a highly conserved enzyme that is essential for viability. In cells, the casein kinase II fl-subunit is phosphorylated 
at an autophosphorylation site and at a site (Ser-209) that is maximally phosphorylated in mitotic cells. To identify protein kinase 
activities that phosphorylate S r-209, we fractionated extracts from mitosis-arrested human Burkitt lymphoma MANCA cells. A single 
Ser-209 kinase activity was detected following each fractionation step. The Ser-209 kinase was purified to a specific activity of approx. 
250 nmol/min per mg and efficiently phosphorylated histone HI, a synthetic peptide containing Ser-209 (Ser-209 peptide), myelin basic 
protein and casein. Immunoblot analysis demonstrated that all fractions containing Ser-209 kinase activity contained p34 cdc2. Further- 
more, depletion of the Ser-209 kinase activity with pl3~UcI-Sepharose and anti-p34 cdc2 antiserum demonstrated conclusively that the 
isolated Ser-209 kinase is p34 cac2. These studies provide strong biochemical evidence that p34 cdc2 is the enzyme that phosphorylates 
Ser-209 on the /3-subunit of CKII in mitotic cells. In addition, these results indicate that the Ser-209 peptide can be utilized as a specific 
reagent for the assay of p34 cdc2 activity in mitotic extracts, since no other Ser-209 peptide kinase activities were detected. 
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1. Introduction 
Casein kinase II (CK]I) is a ubiquitous protein 
serine/threonine kinase that has been implicated in the 
regulation of events controlling the proliferation of cells 
[1-4]. Gene disruption studies in Saccharomyces cere- 
visiae [5], in Schizosaccharomyces pombe [6] and in Dic- 
tyostelium discoideum suggest hat the catalytic activity of 
CKII is required for viability [7]. The enzyme has been 
localized in the cytoplasm and the nucleus of cells [8,9] 
and is known to phosphorylate a number of proteins in 
each of these compartments. Of particular interest o a role 
in the regulation of cell proliferation is the demonstration 
that phosphorylation by CKII can control the DNA binding 
activity of several nuclear regulatory proteins, including 
c-Jun, c-Myb, Serum response factor, Max, the PU. 1/NF-  
EM5 complex and the p53 tumour suppressor ( eviewed in 
Ref. [4]). 
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CKII is a tetrameric enzyme composed of two catalytic 
subunits (a-  and/or  a' - )  as well as two non-catalytic 
fl-subunits that appear to enhance the kinase activity of the 
enzyme [1-4]. CKII is defined as a messenger-independent 
protein kinase since its activity is not directly affected by 
cyclic nucleotides, calcium or diacylglycerol. A number of 
studies have suggested that CKII may be regulated by 
phosphorylation. The studies of Ackerman et al. [10], 
Mulner-Lorillon et al. [11] and Sanghera et al. [12] suggest 
that phosphorylation may be involved in activation of 
CKII activity. By comparison, the studies of Agostinis et 
al. [13] demonstrated that dephosphorylation f CKII is 
associated with an increase in CKII activity. To resolve 
apparent discrepancies in the studies described above and 
to define the role of phosphorylation i  regulating the 
functions of CKII in cells, it is necessary to identify 
phosphorylation sites on CKII and to identify the enzymes 
that phosphorylate these sites. In human epidermal carci- 
noma A431 cells, Ackerman et al. [10], observed that the 
/3-subunit of CKII is phosphorylated. We subsequently 
demonstrated that in exponentially growing cells the major 
site of phosphorylation on CKII /3 is an autophosphoryla- 
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tion site [14] which has been identified as Ser-2 and/or 
Ser-3 [14-16]. The /3-subunit of CKII was also shown to 
be phosphorylated in A431 cells at Ser-209, a residue that 
is phosphorylated in vitro by p34 cdce [14]. An examination 
of the phosphorylation state of CKII at different stages in 
the cell cycle indicated that Ser-209 is maximally phospho- 
rylated in mitotic cells [17]. The latter observation is 
consistent with the conclusion that Ser-209 is a physio- 
logical target of p34 cdc2. However, as noted by Nigg [18], 
this result does not exclude the possibility that this residue 
could be phosphorylated by other protein kinases in cells. 
In particular, since Ser-209 is followed by a proline residue, 
it could be a target for other proline-directed protein 
kinases [19-21]. In this regard it is noteworthy that p34 ~d~2 
and mitogen activated protein kinases can phosphorylate 
identical residues on nuclear lamins [22]. In the present 
study, we utilized a synthetic peptide modelled after the 
region of CKII /3 that contains Ser-209 to detect kinase 
activities in fractionated extracts from mitotic cells that 
can phosphorylate Ser-209 and demonstrate that mitotic 
cells contain a single Ser-209 kinase. Utilizing a simple 
protocol involving sequential chromatographic procedures, 
the Ser-209 kinase was highly purified and conclusively 
identified as p34 cd~2. The identification of p34 cd~2 as the 
only Ser-209 kinase in extracts of mitotic cells provides 
biochemical evidence that reinforces the conclusions that 
the /3-subunit of CKII is a physiological target of p34 c~2. 
Furthermore, our results imply that the Ser-209 peptide can 
be utilized as a specific substrate for the assay of p34 ~c2 
kinase activity in mitotic cells. 
2. Materials and methods 
2.1. Materials 
Human Burkitt lymphoma cells, MANCA [23], were 
obtained from Dr. P. Whyte (McMaster University, Hamil- 
ton, Canada). Synthetic peptides including the Ser-209 
peptide based on the carboxy terminal domain of CKII /3 
(QLQLQAASNFKSPVKTIR) [14], the CKII substrate pep- 
tide (RRRDDDSDDD) [24] and the $6 peptide (RRLS- 
SLRA) [25] were synthesized on an Applied Biosystems 
Model 431A peptide synthesizer using Fmoc chemistry 
and were HPLC-purified on a C18 reverse-phase column 
(Waters DeltaPak). The Myb peptide (ARRPRHSIYSSD- 
DDEEDVE) [26] was synthesized by the Chemical Synthe- 
sis Facility at the Howard Hughes Medical Institute (Uni- 
versity of Washington, Seattle) as previously described. 
Rabbit antisera directed against he carboxy terminus of 
human p34 cdc2 were generated by immunizing rabbits with 
a synthetic peptide (CLDNQIKKM) corresponding to 
residues 290-297 of p34 cat2 coupled to keyhole limpet 
hemocyanin as previously described [14]. These antisera 
do not show any reactivity with CDK2. Mouse monoclonal 
antibodies that recognize human cyclin B 1 (clone GNS-1) 
were obtained from Pharmingen. Rabbit antisera directed 
against fluorosulfonylbenzoyladenosine [27] were a gener- 
ous gift of Dr. R. Geahlen, Purdue University, West 
Lafayette, IN. The bacterial strain overproducing p13 ~uc~, 
the sucl gene product of Schizosaccharomyces pombe 
[28], was generously provided by Dr. P. Nurse (Oxford 
University). Sephacryl S-300 HR, DEAE-Sephacel and 
CNBr-activated Sepharose 4B were obtained from Pharma- 
cia while Econo Q and Econo S columns were obtained 
from Bio-Rad. Phosphocellulose P81 paper was obtained 
from Whatman. Casein (partially dephosphorylated), 
myelin basic protein, Protein A Sepharose, leupeptin, apro- 
tinin, phenylmethylsulfonylfluoride, fluorosulfonyibenzoy- 
ladenosine and nocodazole were purchased from Sigma 
and histone H1 was from Boehringer Mannheim. [Y- 
32p]ATP was obtained from ICN Biomedical. Okadaic 
acid was purchased from Calbiochem and fetal bovine 
serum (Fetalclone II) was obtained from Hyclone. Pow- 
dered RPMI 1640 and Dulbecco's phosphate-buffered 
saline were obtained from Gibco. Reagents for elec- 
trophoresis and immunoblotting including prestained and 
unstained protein molecular weight markers were obtained 
from Bio-Rad. Purified MAP kinase (recombinant ERK2) 
was a generous gift from Dr. Natalie Ahn (University of 
Colorado at Boulder). 
2.2. Preparation of extracts from MANCA cells 
MANCA cells were cultured at 37°C in RPMI-1640 
containing 25 mM Hepes (pH 7.4) and 10% fetal bovine 
serum in an atmosphere of 5% CO 2. Cells were routinely 
maintained at a concentration of 1-5 × 105 cells/ml. To 
obtain populations of MANCA cells that were enriched in 
cells arrested in mitosis, cells were treated with 0.1-0.2 
/zg/ml nocodazole in dimethylsulfoxide for 12 h. Cells 
were harvested by centrifugation at 4°C and washed once 
with ice-cold phosphate-buffered saline containing 0.1 
/zg/ml nocodazole. All subsequent manipulations were 
performed at 0-4°C. The cells were resuspended at a 
concentration f 5 × l0  7 cells/ml in extraction buffer (25 
mM Tris-C1 (pH 7.5), 60 mM /3-glycerophosphate, 15 mM 
EGTA, 15 mM MgC12, 0.5 /xM okadaic acid, 1 mM 
dithiothreitol) containing freshly added proteinase in- 
hibitors (10 /zg/ml leupeptin, 1 mM phenylmethyl- 
sulfonylfluoride, 0.1% aprotinin). For large-scale prepara- 
tions (i.e., exceeding 1× 109cells), 10 mM NaF was uti- 
lized as an economical alternative to okadaic acid as an 
inhibitor of protein phosphatases. Cells were disrupted by 
sonication (2 × 10 s) on ice and sonicates were centrifuged 
for 30 min at 13000 rpm in a Sorvall SS-34 rotor. These 
post-mitochondrial supernatant fractions typically had a 
protein concentration of approx. 3 mg/ml as determined 
by the Bradford assay [29] using bovine serum albumin as 
a standard. To analyse Ser-209 kinase activities in the 
particulate fraction, the pellets following centrifugation 
were washed once with extraction buffer and were then 
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resuspended in the original volume of extraction buffer 
using 20 strokes of a Dounce homogenizer. 
2.3. Chromatographic fraetionation 
For analytical separations (up to 2 × 108 cells) cell 
extracts prepared as described above were subjected to 
fractionation on a Sephacryl S-300 HR column (1.6 × 100 
cm) using buffer A (25 mM Tris-C1 (pH 7.5), 60 /3- 
glycerophosphate, 2 mM EGTA, 5 mM MgC12, 1 mM 
DTT) containing 200 mM NaC1 at a flow rate of 0.25 
ml/min. For the separation of larger quantities of cell 
extract (up to 3 X 10 9 cells), extracts were concentrated by
ammonium sulfate precipitation. Briefly, solid ammonium 
sulfate (0.08 g/ml) was added slowly to the extract with 
stirring at 0°C. The extract was stirred for an additional 1 h 
at 0°C and was then cl~trified by centrifugation. Solid 
ammonium sulfate (0.141 g/ml) was then added to the 
supernatant with stirring. After an additional hour of stir- 
ring, precipitated material was collected by centrifugation 
and then resuspended in 5-10 ml of buffer A containing 
10 mM NaF. There were no significant differences in the 
elution profiles of Ser-209 kinase activities on Sephacryl 
S-300 HR between extracts that were directly applied to 
the column or extracts that were concentrated by ammo- 
nium sulfate precipitation prior to application to the col- 
umn. Following fractionation on Sephacryl S-300 HR, 
fractions containing Ser-299 kinase activity were pooled 
and dialyzed for 4 h against at least 20 volumes of buffer 
A containing 10 mM NaF. The dialyzed material was then 
loaded at a flow rate of approximately 0.25 ml/min on to 
a 15-ml DEAE-Sephacel column that had been pre-equi- 
librated with Buffer A containing 10 mM NaF. The col- 
umn was washed with 30 ml of buffer A prior to elution of 
bound proteins with a 90-ml linear gradient (0-0.5 M 
NaCI in buffer A). Fractions containing Ser-209 kinase 
activity were pooled and dialyzed against buffer A as 
described above prior to loading on a 5-ml Econo Q 
column that had been pre-equilibrated with buffer A. The 
column was subsequently washed with 15 ml of buffer A 
before bound proteins were eluted with a 75-ml linear 
gradient (0-1.0 M NaCI irL buffer A). Fractions containing 
Ser-209 kinase activity were pooled, dialyzed versus buffer 
B (25 mM Hepes (pH 7.5), 60 mM /3-glycerophosphate, 5 
mM MgC12, 2 mM EGTA, 1 mM DTT) and loaded onto a 
5-ml Econo S column. The column was washed with 15 ml 
of buffer B and bound material eluted with a 75-ml linear 
gradient (0-1.0 M NaC1 in buffer B). Fractions containing 
Ser-209 kinase activity were stored on ice where signifi- 
cant levels of activity wen. ~ retained for several weeks. 
2.4. Kinase assays 
Ser-209 kinase activity was measured at 30°C in a 
30-~1 reaction mixture containing 30 mM Tris-C1 (pH 
7.5), 10 mM MgC12, 1 rnM dithiothreitol, 0.1 mM ATP 
(spec. act. 400-1000 cpm/pmol) and 0.25 mM Ser-209 
peptide. Reactions were initiated by the addition of en- 
zyme and terminated by spotting 20 /zl of the reaction 
mixture on phosphocellulose P81 paper as previously de- 
scribed [30]. Additional substrates were similarily assayed 
at the following concentrations: myelin basic protein (0.4 
mg/ml), histone H1 (0.4 mg/ml), the CKII substrate 
peptide RRRDDDSDDD (0.1 mM), Myb peptide (0.2 
mM), $6 peptide (0.25 mM) and casein (1 mg/ml). One 
unit of kinase activity is defined as the amount of enzyme 
required to transfer one nmol of phosphate to substrate per 
minute at 30°C. 
2.5. Depletion of  Ser-209 kinase 
P13 ~ucl was expressed in bacteria s described [28] and 
coupled to CNBr-activated Sepharose at a concentration f
1 mg protein/ml of gel as described by the manufacturer. 
Depletion of p34 c~c2 and related protein kinases from 
Ser-209 kinase preparations was performed by incubating 
an aliquot (15 /zl) of the purified kinase with 30 /zl of 
pl3~Ucl-Sepharose (1:1 vol/vol in phosphate-buffered 
saline) in a total volume of 45 /zl. Control depletions were 
performed by incubating the purified kinase with 30 /~1 of 
protein A Sepharose (1:1 vol/vol in phosphate-buffered 
saline). After incubation at 4°C for 1 h with gentle tum- 
bling, the Sepharose was pelleted by centrifugation and 
kinase activity in the supernatant was measured as de- 
scribed above. Immunodepletion f p34 cdc2 from Ser-209 
kinase preparations was performed by incubating an aliquot 
of purified enzyme (20 /xl) with antisera (4 /xl) directed 
against he carboxy terminus of human p34 cd~2 and protein 
A Sepharose (20 /xl of 1:1 v /v  in Phosphate buffered 
saline) with gentle tumbling for 2 h at 4°C. Control 
depletions utilized pre-immune serum from the same rab- 
bit. After removal of immune complexes by centrifugation, 
kinase activity in the supernatant was determined as de- 
scribed above. 
2.6. Other procedures 
Protein determinations were obtained using the Brad- 
ford assay with bovine serum albumin as standard [29]. 
Gel electrophoresis was performed in 12% gels by the 
method of Laemmli [31 ] and stained using a silver stain kit 
from Bio-Rad. The purified Ser-209 kinase was reacted 
with fluorosulfonylbenzoyladenosine by modification of 
the method of Atherton-Fessler t al. [32] as follows. 
Briefly, fluorosulfonylbenzoyladenosine was dissolved in 
dimethylsulfoxide at a concentration of 5 mM. Purified 
Ser-209 kinase was incubated with 0.5 mM fluorosulfonyl- 
benzoyladensoine and 10 mM MgC12 for 30 min at 30°C 
in the presence or absence of 2 mM ATP. Reactions were 
terminated by the addition of Laemmli sample buffer and 
heated for 15 min at 37°C [31]. For immunoblot analysis, 
proteins were subjected to SDS-polyacrylamide g l elec- 
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trophoresis and transferred to nitrocellulose as described 
by Towbin et al. [33] using a Bio-Rad transblot apparatus. 
Filters were blocked with 3% gelatin as previously de- 
scribed [17] and incubated with rabbit anti-p34 cdc2 antisera 
(1:1000), mouse anti-cyclin B1 (1:1000) or with rabbit 
anti-fluorosulfonylbenzoyladenosine (1:1000) for at least 1 
h at room temperature. Immune complexes were detected 
with goat anti-rabbit alkaline phosphatase-conjugated nti-
bodies using 5-bromo-4-chloro-3-indoyl phosphate and ni- 
troblue tetrazolium as substrate. 
3. Results 
3. I. Chromatographic fractionation of mitotic extracts 
Since Ser-209 on the /3-subunit of CKII is maximally 
phosphorylated in mitotic cells [17], post-mitochondrial 
fractions prepared from cells arrested in mitosis were 
utilized as a source of material for the identification and 
purification of Ser-209 kinase activities. In order to pre- 
vent dephosphorylation and inactivation of protein kinases 
that may be regulated by phosphorylation, the extraction 
buffer contained phosphatase inhibitors including /3- 
glycerophosphate, NaF, or okadaic acid. To monitor Ser- 
209 kinase activity, we measured the phosphorylation f a 
synthetic peptide modelled after the carboxyl terminus of 
the CKII /3-subunit [14]. In initial experiments, mitotic 
extracts from Manca cells (2 × 108 cells) were subjected 
to fractionation by gel filtration on Sephacryl $300 HR 
yielding a single peak of Ser-209 kinase activity similar to 
that shown in Fig. l a (data not shown)• Furthermore, 
examination of Ser-209 kinase activity in the post-mito- 
chondrial and particulate fractions obtained following dis- 
ruption of mitotic cells by sonication indicated that the 
activity was primarily in the post-mitochondrial fraction 
and that the particulate fraction contained only 10% of the 
total activity (data not shown). We do not know if the 
activity detected in the particulate fraction is the same as 
the activity in the post-mitochondrial fraction or if it 
represents a distinct Ser-209 kinase activity. However, 
further efforts were directed towards analysis of the post- 
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Fig. 1. Sequential fractionation of Ser-209 kinase activity. Mitotic extracts were prepared from 3 × 109 Manca cells and sequentially fractionated by gel 
filtration on Sephacryl S-300HR (a) followed by ion exchange on DEAE-Sephacel (b), Econo Q (c) and Econo S (d) as described in Section 2. 
Incorporation of 32p from [7-32p]ATP into the Ser-209 peptide (indicated by open squares) was measured as described in the Section 2. Fractions 
containing Ser-209 kinase activity were pooled as follows: Sephacryl $300 HR, fractions 28-38; DEAE-Sephacel, fractions 19-31; and Econo Q, fractions 
12-18. The NaC1 gradient for ion exchange fractionations is indicated by the straight dashed line on panels b,c,d. The protein elution profile determined by 
the Bradford assay is illustrated by the dotted line. 
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Table 1 
Purification of Ser-209 kinase from 3 × 109 Manca cells 
Sample Total protein Specific activity Recovery Purification 
(mg) (nmol/min/mg) % (-fold) 
Extract 210 0.008 
S300HR 41.6 5.4 100 1 
DEAE 6.4 19.1 55 3.5 
Econo Q 1.8 60.2 48 11.1 
Econo S Peak 0.11 259 13 48.0 
Ser-209 kinase activity was determined as described in the experimental 
section. Values presented are tho,;e from a representative preparation. As 
described in the text, Ser-209 kinase activity cannot be accurately mea- 
sured in the crude extract. Therefore, the recovery and purification are 
expressed relative to the S300HR pool 
mitochondrial Ser-209 kin~tse activity, since the particulate 
activity represented a ver.¢ small proportion of  the total 
Ser-209 kinase activity measured. 
To facilitate efforts to fractionate larger quantities of  
material (i.e., f rom 3 × 109 cells), proteins from mitotic 
extracts were concentrated by ammonium sulfate precipita- 
tion prior to sequential fractionation by gel filtration on 
Sephacryl S-300 HR and by ion exchange chromatography 
on DEAE Sephacel, Econo Q and Econo S columns (Fig. 
1). When fractions from each column were assayed for 
Ser-209 kinase activity, a single peak of  activity was 
observed. These results suggest that the Ser-209 peptide 
was a specific substrate tbr the protein kinase that was 
being purif ied but do not exclude the possibil ity that 
distinct Ser-209 kinases raay have cofractionated uring 
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Fig. 2. Substrate specificity of Ser-209 kinase. Purified Set-209 kinase 
from the Econo S column was examined for its ability to phosphorylate 
the following substrates: 0.25 mM RRLSSLRA peptide ($6), 0.4 mg/ml 
myelin basic protein (MBP), 0.4 mg/ml histone H1 (HI), 0.1 mM CKII 
substrate peptide RRRDDDSDDD (DSD), 0.25 mM Ser-209 peptide 
(Ser-209), 0.2 mM Myb peptide (Myb), and 1 mg/ml casein (casein). 
Assays were performed in duplicate for 4 min at 30°C. To ensure that 
assays were linear, assays were performed so that less than 15% of the 
substrate was utilized. Results :shown represent the average of results 
obtained with two independent preparations of Ser-209 kinase (range is 
indicated by error bars). 
Fig. 3. Immunoblot analysis of Ser-209 kinase with anti-p34 cd~2 anti- 
serum. Fractions from each stage of the purification of Ser-209 kinase 
were subjected to SDS-polyacrylamide g l electrophoresis on a 12% gel 
and transferred tonitrocellulose for immunoblot analysis with anti-p34 cdc2 
antiserum. The following samples were analyzed; initial extract (lane 1), 
Sephacryl $300 HR pool (lane 2), DEAE-Sephacel pool (lane 3), Econo 
Q pool (lane 4) and Econo S peak (lane 5). Equivalent amounts of 
Ser-209 kinase activity were analyzed in lanes 2-5. The position of 
prestained molecular weight markers is indicated. The identity of these 
markers and their approximate molecular weights (from top to bottom) 
are as follows: phosphorylase b (139 900), bovine serum albumin (86 800), 
ovalbumin (47800), carbonic anhydrase (33300), soybean trypsin in- 
hibitor (28600) and lysozyme (20700). 
the purification process. The results of  a typical Ser-209 
kinase purification from 3 × 109 human Manca cells are 
summarized in Table 1. It is l ikely that the activity mea- 
sured in the initial extract was significantly underestimated 
because of  the presence of  inhibitors or enzymes that may 
interfere with the detection of  Ser-209 kinase activity. In 
this regard, the initial extraction buffer contained NaF, a 
phosphatase inhibitor that is also known to inhibit the 
activity of  protein kinases including CKI I  and p34 cdcz 
[34,35]. Since the activity of the initial extract does not 
l ikely reflect the actual activity, the percentage recoveries 
at each step were determined relative to the $300 HR pool. 
74 D. W. Litchfield et aL /Biochimica et Biophysica Acta 1269 (1995) 69-78 
The specific activity of the peak fraction of material eluted 
from the Econo S column was approximately 250 
nmol /min /mg with a yield of approx. 13% as compared 
to the activity of the $300 HR pool. Other purified prepa- 
rations of Ser-209 kinase from Manca cells and from 
human Jurkat cells had similar specific activities (data not 
shown). 
copurified. Similarly, myelin basic protein is routinely 
used as a substrate for various forms of MAP kinase, and 
can be phosphorylated by a number of other protein ki- 
nases [22,38]. Consequently, the observation that our Ser- 
209 kinase preparation exhibited myelin basic protein ki- 
nase activity raised the possibility that more than one 
protein kinase was present in the preparation. 
3.2. Substrate specificity of  Ser-209 kinase 
To assess the specificity of the Ser-209 kinase, a variety 
of different proteins or peptides were tested as substrates 
for the enzyme (Fig. 2). Histone HI,  myelin basic protein 
and casein were also substrates for the Ser-209 peptide 
kinase. Synthetic peptide substrates including RRRDDDS- 
DDD and a Myb peptide (ARRPRHSIYSSDDDEEDVE), 
both of which are substrates for CKII, were not phospho- 
rylated nor was the $6 peptide (RRLSSLRA). The latter 
peptide can be phosphorylated in vitro by a number of 
purified protein kinases, including p90 RsK, cAMP-depen- 
dent protein kinase and members of the protein kinase C 
family [36]. The ability of the Ser-209 kinase to phospho- 
rylate histone HI and casein is consistent with the ex- 
pected substrate specificity of p34 ~dc2 [37]. However, since 
each of these proteins are known to be in vitro substrates 
for a number of distinct protein kinases, it is not possible 
to exclude the possibility that distinct protein kinases were 
3.3. Immunodetection f p34 'd`2 and SDS-polyacrylamide 
gel electrophoresis 
Since it was anticipated that p34 cdc2 would be one 
potential Ser-209 kinase [14], fractions obtained following 
fractionation on Sephacryl S-300 HR were analyzed for 
the presence of p34 cdc2. Immunoblot analysis of individual 
fractions (data not shown), demonstrated the presence of 
two distinct peaks of immunoreactive material with a 
molecular weight on immunoblots of approximately 34 000. 
The initial peak of immunoreactive material corresponded 
with the fractions that contained Ser-209 kinase activity, 
whereas the second less prominent peak of immuno- 
reactive material displayed no Ser-209 kinase activity. We 
presume that the inactive peak of p34 cd~2 is a monomeric 
protein that was not complexed to a cyclin. The higher 
molecular weight of the active peak of material is consis- 
tent with the presence of associated proteins. Cyclin B1 
was detected in the Ser-209 kinase preparation obtained 
a 
b 
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Fig. 4. Immunoblot analysis and SDS-polyacrylamide gelelectrophoresis of purified Ser-209 kinase. Fractions eluted from the Econo S column were 
analysed on immunoblots developed with anti-cyclin BI antibodies (a), anti-p34 cdc2 antibodies (b) or were examined for Ser-209 kinase activity (c). The 
peak fractions were also subjected toSDS-polyacrylamide gel electrophoresis (d) on a 12% gel and proteins visualized by silver staining. Arrows are used 
to indicate the presence ofcyclin B1 (a, upper arrow on d) and p34 cdc2 (b, lower arrow on d). For immunoblots (a,b) 25 /zl of each fraction were analysed, 
while 75 /xl of each fraction were analysed by gel electrophoresis (d). Molecular weight markers (d) from top to bottom are as follows: phosphorylase b 
(97400), bovine serum albumin (66 200), ovalbumin (43 000), carbonic anhydrase (31 000) and soybean trypsin inhibitor (21500). 
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following Econo S fractionation (see Fig. 4). Immunoblots 
also demonstrated the presence of p34 ~dc2 in each of the 
pooled fractions of Ser-209 kinase (Fig. 3). 
To further analyse the most highly purified preparations 
of Ser-209 kinase, we employed SDS-polyacrylamide g l
electrophoresis and immunoblot analysis with anti-p34 ~d~2 
and with anti-cyclin B1 (Fig. 4). Cyclin B 1 (Fig. 4a) and 
p34 cdc2 (Fig. 4b) are present in the fractions that exhibit 
the highest levels of Ser--209 kinase activity (Fig. 4c). 
Furthermore, electrophoretic analysis of the active frac- 
tions from the Econo S column (Fig. 4d) revealed the 
presence of bands of approximate molecular weights 60 000 
(dark staining) and 34 000 (negatively staining) that comi- 
grated with the cyclin B I and p34 ~dc2 staining seen on 
immunoblots. Collectively, these results, suggest that 
p34 ca~2 and cyclin B 1 comribute to the measured Ser-209 
kinase activity, but do not establish whether other distinct 
protein kinases are present and contribute to the observed 
Ser-209 kinase activity. 
3.4. Depletion of Ser-209 kinase 
To determine to what extent p34 cd~2 contributed to the 
measured Ser-209 kinase activity, the purified material was 
depleted utilizing p13 '~ucl attached to Sepharose [28] and 
by immunoprecipitation with antipeptide antibodies di- 
rected against he carboxy terminus of p34 ~d~2 [14,17,37]. 
P13 ~u~l is the product of the fission yeast sucl gene which 
forms a stable complex with p34 cd~2 or related kinases 
from a variety of species. As shown in Fig. 5, treatment of
the purified Ser-209 kinase with p 13sucl-Sepharose resulted 
in depletion of approx. 80% of the kinase activity towards 
(a) 
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Fig. 5. Depletion of Ser-209 kinase with pl3~Ucl-Sepharose and with anti-p34 cd~2 antiserum. Purified Ser-209 kinase was incubated with pI3 ~u~1-Sepharose 
(a-c, open squares), with protein A Sepharose (a-c, open circles), with anti-p34 cdc2 serum and protein A Sepharose (d-f, open squares), or with 
preimmune serum and protein A Sepharose (d-f, open circles) as described in Section 2. After removal of beads by centrifugation, kinase activity in the 
supernatant fraction was measured for 2.5, 5 or 10 min at 30°C with myelin basic protein (a,d), Ser-209 peptide (b,e) or histone HI (c,f) as substrate. 
Relative kinase activities are expressed as a percentage of the maximal kinase activity that was observed. For p13 ~u~l depletion (a-c), the maximal kinase 
activity was measured in a 10-rain assay with the supernatant fraction obtained after incubation of Ser-209 kinase with protein A Sepharose. For 
anti-p34 ¢dc2 depletion (d-f), the maximal kinase activity was measured in a 10-min assay with the supernatant fraction obtained after incubation of Ser-209 
kinase with pre-immune serum. 
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histone HI, myelin basic protein and Ser-209 peptide as 
compared to the activity that remained following treatment 
of the Ser-209 kinase with protein A-Sepharose. Activity 
remaining after incubation of Ser-209 kinase with phos- 
phate-buffered saline was similar to that observed with 
protein A-Sepharose, indicating that Ser-209 kinase is 
unaffected by protein A (data not shown). Since p13 ~ucl 
could be interacting with enzymes distinct from p34 ~2, 
depletion experiments were repeated using specific anti- 
p34 cd~2 antibodies. By comparison with control depletions 
performed using pre-immune serum, the anti-p34 ~dc2 anti- 
bodies removed greater than 90% of the activity measured 
with the Ser-209 peptide, histone H1 and myelin basic 
protein in a single round of immunoprecipitation. Im- 
munoblots of the immunoprecipitates and the supernatants 
following immunoprecipitation i dicated that a small 
amount of p34 c~c2 remained in the supernatant following 
immunoprecipitation (data not shown). As an additional 
test of its kinase purity, purified Ser-209 kinase was 
incubated with fluorosulfonylbenzoyladenosine in the pres- 
ence or absence of ATP and then analyzed on im- 
munoblots developed with anti-fluorosulfonylbenzoyla- 
denosine antibodies [27]. The most visible band on these 
blots could be competed with an excess of ATP and 
comigrated with the M r 34000 band that was detected 
with anti-p34 cd~2 antisera (data not shown). Additional 
bands that were visible on these blots were not competed 
with ATP, suggesting that they are not ATP-binding pro- 
teins and may react non-specifically with fluorosulfonyl- 
benzoyladenosine or the anti-fluorosulfonylbenzoyladeno- 
sine antisera. Collectively, these results indicate that the 
activity of Ser-209 kinase is derived exclusively from the 
p34 cd~2 protein kinase. We obtained no evidence that the 
Ser-209 kinase preparations contained protein kinases that 
are distinct from p34 ~c2. 
4. Discussion 
CKI I  is a messenger - independent  protein 
serine/threonine kinase that could itself be regulated by 
phosphorylation [ 10-13]. Since there are apparent discrep- 
ancies in how CKII is actually affected by phosphoryla- 
tion, it is important to determine which protein kinases are 
actually responsible for the phosphorylation of CKII in 
cells. Towards this objective, we previously demonstrated 
that the /3 subunit of CKII is phosphorylated at Ser-209 in 
cells, and showed that Ser-209 can be phosphorylated in 
vitro by immunoprecipitated p34 cac2 [14]. However, since 
the substrate specificity of p34 cdc2 is similar to that of a 
number of other proline-directed protein kinases [19-22], 
it was very possible as noted by Nigg [18] that enzymes 
distinct from p34 ~dc2 were responsible for the phosphoryla- 
tion of Set-209 in cells. The phosphorylation f Ser-209 is 
significantly greater in mitotic cells than in interphase 
cells, supporting the conclusion that p34 cJc2 could be 
responsible for phosphorylation of that residue. However, 
the involvement of distinct enzymes that could also be 
active in mitotic cells was not examined. Utilizing a 
biochemical fractionation approach, the present study pro- 
vides evidence that the major, and probably the only, 
enzyme in mitotic cells that phosphorylates Ser-209 on the 
CKII /3 subunit is p34 cdc2. 
Although the primary objective of this study was di- 
rected towards identification of the enzymes that phospho- 
rylate CKII in intact cells, our results indicate that we have 
developed a relatively simple procedure for the purifica- 
tion of p34 cd~2 without the involvement of pl3~UcJ-Sep - 
harose. In this regard, the ability of p13 ~u~j to interact with 
protein kinases distinct from p34 cdc2 or to alter the activity 
of p34 cdc2 in a substrate-specific manner may be problem- 
atic [28,39-43]. The purification procedure stablished in 
this study provides a convenient method for the prepara- 
tion of p34 cdc2 for studies in which the activity of this 
enzyme is required in order to investigate its effects on 
substrate proteins. Our results also indicate that the Ser-209 
peptide can be used as a specific substrate for the measure- 
ment of p34 cdc2 kinase activity in fractionated mitotic 
extracts. We cannot exclude the possibility that the Ser-209 
peptide could be phosphorylated by other proline-depen- 
dent protein kinases (i.e., MAP kinase, CDK5) in extracts 
prepared at other stages during the cell cycle. However, it 
is unlikely that MAP kinase is involved in the phospho- 
rylation of Ser-209 since partially purified MAP kinase 
does not appear to phosphorylate purified CKII in vitro, 
nor does the phosphorylation of Ser-209 increase in re- 
sponse to factors that activate MAP kinase [14,17]. Fur- 
thermore, when p34 cd~2 and MAP kinase (normalized ac- 
cording to myelin basic protein phosphorylation) were 
used to phosphorylate he Ser-209 peptide, the peptide was 
phosphorylated more than 30-fold more efficiently by 
p34 c°c2 (data not shown). CDK5 has a substrate specificity 
that is very similar to that of p34 cdc2, but its expression is 
specific to differentiated neuronal cells [44,45]. Impor- 
tantly, under the conditions used in these studies with 
extracts prepared from mitotic cells, the Ser-209 peptide 
appears to be specific for p34 cdc2. The ability of myelin 
basic protein to be efficiently phosphorylated by p34 ~dc2 as 
noted in this study and in previous work [46] raises 
concerns regarding its use as a substrate for other protein 
kinases. In particular, myelin basic protein is routinely 
used as a substrate for members of the MAP kinase family 
when assaying crude cell extracts and column fractions 
[38]. Results presented in this study certainly indicate that 
the identification of any enzyme cannot be established 
solely on its ability to phosphorylate any particular sub- 
strate unless that substrate can be demonstrated to be a 
specific substrate under the assay conditions being utilized. 
The demonstration that CKII is a substrate for p34 cd~2 
suggests that the functions of CKII are regulated uring 
the cell cycle. In this regard, there have been observations 
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in amphibian or starfish ooeytes and in mammalian fibrob- 
lasts that there are alterations in CKII activity at different 
stages in the cell cycle [47-50]. Also, cells will not 
progress through the cell cycle if they are microinjected 
with anti-CKII antibodies [:51 ] or if the expression of CKII 
is blocked with antisense oligonucleotides [52]. Further- 
more, the studies of Mulner-Lorillon et al. [11] showed 
that a significant increase in CKII activity was measured 
when CKII purified from Xenopus laevis was phospho- 
rylated in vitro by p34 cdc2 from Starfish oocytes at an 
unidentified threonine residue on CKII /3. The physio- 
logical significance of these findings remains unknown 
since the threonine phosphorylation site on the CKII /3 
subunit was not identified. Also, we obtained no evidence 
that any threonine residues are phosphorylated on mam- 
malian CKII /3 in cells or in vitro by p34 cd~2 and have not 
observed any direct effects of phosphorylation by p34 cd~2 
on the activity of CKII [171]. At this time, we are unable to 
resolve the discrepancies between our data and the results 
of Mulner-Lorillon et al. [ 11 ]. Future studies involving the 
overexpression f the CKII /3 subunit with mutations at 
Ser-209 in mammalian cells may illuminate more precisely 
how phosphorylation f this residue controls the functional 
properties of CKII during cell cycle progression. 
Overall, to understand how CKII is involved in cell 
cycle progression, and hove it may be regulated by phos- 
phorylation, it is necessary to identify the enzymes that are 
involved in the phosphorylation f CKII in cells. Since the 
role of p34 ~d~2 in the initiation of mitotic events is well 
established [53-55], the demonstration that CKII is a 
substrate for p34 cdc2 is very signifcant. The activation of 
p34 ~dc2 at the G2/M tran,;ition is associated with a dra- 
matic increase in the phosphorylation of many proteins 
[56] and with dramatic changes in the cell that allow 
division to occur. Even if 'the catalytic activity of CKII is 
not directly affected by phosphorylation, it is possible that 
its functional properties could be regulated by phospho- 
rylation in a manner that its ability to recognize certain 
substrates or its access to substrates i affected. Changes in 
functional properties resu]iting from phosphorylation by 
p34 ~d~2 could indicate that CKII participates with p34 ~dc2 
in mediating the burst of phosphorylation that accompanies 
entry into mitosis. In this wein, it has been demonstrated by
immunolocalization studies that CKII becomes associated 
with the mitotic spindle [8,9]. Interestingly, it has also been 
demonstrated by Cardenas et al. [57] in yeast hat topoiso- 
merase II is more significantly phosphorylated at mitosis 
than in interphase. When yeast with a temperature-sensi- 
tive CKII are shifted to the non-permissive t mperature, 
phosphorylation f topoisomerase II is barely detectable, 
suggesting that CKII is responsible for its phosphorylation 
in mitosis. To fully appreciate he functions of CKII during 
different stages of the cell cycle, it will be necessary to 
extend these studies to identify other CKII substrates and 
to determine at what stage these substrates are actually 
phosphorylated. 
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